FDA Inspection
Sunrise Pharmaceutical, Inc.Sunrise Pharmaceutical, Inc. – FDA Inspection, Mar 31, 2026
Record Details
This FDA Inspection record concerns Sunrise Pharmaceutical, Inc., with an inspection on March 31, 2026, issued by the New Jersey District Office, covering human drugs.
View Company Profile
ID · 134a0df6-db17-42bb-a748-6fdef717a55f
Inspection Facts
- Inspection number
- 1310416
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
1- 21 CFR 211.142(b)Storage under appropriate conditions
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Sunrise Pharmaceutical, Inc.
8| Date | Classification | Office | Project area |
|---|---|---|---|
| January 27, 2023 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| January 18, 2018 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| June 22, 2017 | Not classified | New Jersey District Office | |
| April 6, 2017 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| January 8, 2014 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Sunrise Pharmaceutical, Inc.
- FDA Inspection 1198356 - 2023-01-27
- FDA Inspection 1038016 - 2018-01-18
- FDA Inspection 1016794 - 2017-06-22
- FDA Inspection 1013086 - 2017-04-06
- FDA Inspection 861922 - 2014-01-08
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.